Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824960 | 0.71 | NPC1 (0.46) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5424464 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6261842 | 0.71 | ADORA2A (0.42) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3798990 | 0.71 | CYP1A2 (0.41) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL276859 | 0.71 | ADORA2A (0.42) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL104411 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2007380 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2589546 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL276858 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29822798 | 0.71 | MAOB (0.46) | MEN1NPC1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001358-A | Adjust the new pyridine hepyramine compound of istone lysine demethylase (KDM) catalytic activity | 东亚ST株式会社 | 2017-08-01 | — | — | CN | claimed |
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| CN-108440515-A | Substituted benzofuranyl and benzoxazole based compound and application thereof | 卡尔约药物治疗公司 | 2018-08-24 | — | — | CN | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| CN-105492437-B | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | 卡尔约药物治疗公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-107001358-A | Adjust the new pyridine hepyramine compound of istone lysine demethylase (KDM) catalytic activity | 东亚ST株式会社 | 2017-08-01 | — | — | CN | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5684015-A | ANGIOTENSIN ANTAGONIST AS HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0702013-A2 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1996-03-20 | — | — | EP | disclosed |
| US-5438063-A | Hypotensive agents, cardiac insufficiency, increased intraocular pressure, and CNS disorders | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0657454-A1 | Imidazopyridazines being angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
| US-5389642-A | Exhibit antagonistic properties toward angiotensin(II); useful for treatment of hypertensioni, aldosteronism, cardiac insufficiency, increased intraocular pressure and disorders of the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| EP-0628556-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0602521-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0547514-A2 | Imidazopyridine derivatives with angiotensin-II antagonist properties | MERCK PATENT GmbH (DE) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MEN1 1064/4885NPC1 1968/4885CYP1A2 3371/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MEN1 1064/4885NPC1 1968/4885CYP1A2 3371/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | MEN1 1064/4885NPC1 1968/4885CYP1A2 3371/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | MEN1 2962/4885NPC1 1734/4885CYP1A2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.